Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

479P - Survival outcomes of resected gastroesophageal cancer and impact of active surveillance: Experience from a tertiary centre

Date

27 Jun 2024

Session

Poster Display session

Presenters

Federico Longo Munoz

Citation

Annals of Oncology (2024) 35 (suppl_1): S162-S204. 10.1016/annonc/annonc1482

Authors

J. Chamorro-Pérez1, G. González Martín1, E. Corral de la Fuente1, V. Albarrán Fernández2, D.I. Rosero Rodriguez1, M.V.V. San Roman Gil1, R. Ferreiro Monteagudo1, I. Martínez Delfrade1, B.I. Morón1, B. de Frutos González1, P. Reguera Puertas3, J.J. Serrano Domingo4, M.A. Vaz Salgado1, M.L. Villamayor Delgado1, C. Guillen Ponce1, V. Lopez Gomez1, M. Rodriguez1, A. Carrato Mena1, P. Garrido Lopez1, F. Longo Munoz1

Author affiliations

  • 1 Hospital Universitario Ramon y Cajal, Madrid/ES
  • 2 Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 3 University Hospital of Salamanca, Salamanca/ES
  • 4 Instituto Oncológico Vithas, 28031 - Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 479P

Background

Localized gastroesophageal carcinomas require a multidisciplinary approach. No surveillance protocols have been standardized and their impact on patient’s survival remains elusive. In this study, we aim to expose our experience in this setting.

Methods

We performed a retrospective analysis recruiting all patients diagnosed with gastroesophageal carcinomas treated with surgery in Ramon y Cajal University Hospital. Surveillance protocol consisted of biannual evaluation with tumoral marker CEA and CT scans for the first 3 years. Thereafter, annual visits were conducted for 10 years.

Results

Between 2014 and 2023, 199 patients with localized gastroesophageal tumours underwent surgical treatment. Regarding peri-operative treatment, pre and postoperative chemotherapy was applied in 58.3% and 54,3% respectively. Radiotherapy was used before surgery in 10% of patients and 10% received it after surgery. With a median follow-up of 49.9 months, median disease-free survival (DFS) and overall survival (OS) were not reached. DFS and OS rates at 5 years were 54.7% and 61.45%, respectively. Among 76 relapses, 63.2% were metastatic, 18.4% locoregional and 18.4% had both patterns of relapse. The prognostic factors associated with worse DFS (p<0.005) were primary tumour location, HER2-positive status and TNM stage. Relapses were detected at the planned surveillance in 57.9% of cases with a median OS of 46.6 months. On the other hand, 42.1% were found in unscheduled follow-up due to symptoms derived from the disease, with a median OS of 27.3 months (95%CI 16.8 – 35.9). This difference was statistically different (log-rank p=0.0021) with an HR of 2.37 (95%CI 1.34-4.17).

Conclusions

This study highlights the poorer prognosis of relapses detected in unscheduled follow-up and the potential role of planned surveillance improving survival outcomes. Prospective studies are warranted to design standardized surveillance protocols.

Legal entity responsible for the study

Hospital Universitario Ramon y Cajal; Instituto Ramon y Cajal de Investigación Sanitaria (IRYCIS).

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.